신흥 시장 아웃소싱(2026년 1분기)

This expert outsourcing report is a comprehensive look at the pharmaceutical manufacturing landscape for emerging markets in Q1 2026, including analysis of news and trends affecting contract manufacturing organizations (CMOs) and the identification of recent contract service agreements, mergers, acquisitions, and financing among CMOs. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the pharmaceutical value chain that will provide insights into API (biologics and chemical) as well as dose manufacturing and packaging (clinical and commercial) for countries in emerging markets.

Scope

This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from GlobalData's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for -

• CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
• Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
• Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.

Reasons to Buy

• Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
• Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
• Learn about the past quarter's M&A and financing deals in the manufacturing space.
• Identify the latest contract service agreements.
• Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
• Stay ahead of disruption with updates on supply chain obstacles and new regulations.

Table of Contents

Table of Contents

1 Industry Trends

• 1.1 India's FY2026-27 budget unveils a major policy boost for biologics and biosimilars, tariff exemptions for oncology and orphan drugs
• 1.2 China releases new revision of drug administration law, aiming to spur innovation

2 Industry Analysis

• 2.1 Emerging market contract service agreements
• 2.2 Emerging market quarterly mergers, acquisitions, and financing - Q1 2026

3 Value Chain

• 3.1 API chemical
• 3.2 API biologics (protein and peptide)
• 3.3 API biologics (cell, gene, vaccine, and virus therapies)
• 3.4 Commercial dose manufacturing and packaging
• About the Authors
• About GlobalData
• Contact Us